Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
implications. Academic Radiology 1998;5:282-8. Indexing Status Subject indexing assigned by NLM MeSH Adult; Colonic Polyps /diagnosis /economics; Colonoscopy /economics; ColorectalNeoplasms /diagnosis /economics; Computer Simulation; Cost-Benefit Analysis; Feasibility Studies; Female; Humans; Image Processing, Computer-Assisted /economics; Male; Markov Chains; Mass Screening /economics; Sensitivity and Specificity; Tomography, X-Ray Computed /economics; User-Computer Interface AccessionNumber 21999001546 (...) Is virtual colonoscopy a cost-effective option to screen for colorectalcancer? Is virtual colonoscopy a cost-effective option to screen for colorectalcancer? Is virtual colonoscopy a cost-effective option to screen for colorectalcancer? Sonnenberg A, Delco F, Bauerfeind P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed
. Bibliographic details Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, Czernichow P, Colin R. Postoperative management of stage II/III coloncancer: a decision analysis. Gastroenterology 1999; 117(4): 784-793 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Cohort Studies; ColonicNeoplasms /economics /pathology /therapy; Decision Support Techniques; Health Care Costs; Humans; Neoplasm Staging; Postoperative Care; Sensitivity and Specificity; Survival Analysis (...) Postoperative management of stage II/III coloncancer: a decision analysis Postoperative management of stage II/III coloncancer: a decision analysis Postoperative management of stage II/III coloncancer: a decision analysis Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, Czernichow P, Colin R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods
reported. Study design Retrospective cohort study carried out at a single centre. No patients were lost to follow-up. Analysis of effectiveness The analysis of the clinical study was based on the intention to treat principle. The primary health outcomes used included the number of patients with a colonic source of occult gastrointestinal bleeding, with neoplastic lesions, adenomas, adenomas greater than or equal to 1 cm in diameter, adenocarcinoma, vascular ectasias, ulcerative colitis, Crohn disease (...) . Colorectalcancer screening in asymptomatic populations. Gut 1995;36(4):590-598. Indexing Status Subject indexing assigned by NLM MeSH Colonoscopy /economics; ColorectalNeoplasms /complications /diagnosis /economics; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage /diagnosis /economics /etiology; Humans; Male; Medical Records; Middle Aged; Occult Blood; Predictive Value of Tests; Retrospective Studies; Risk AccessionNumber 21999008269 Date bibliographic record published 29/02/2000 Date
the ULN (in the case of lever metastases, transaminase concentrations of 5 times ULN or less and bilirubin 1.5 times the ULN or less were permitted), and creatinine of 135 micromol/L or less. Patients were excluded if they had undergone prior treatment with topoisomerase I inhibitors, raltitrexed, or oxaliplatin. Also, if they had bulky disease (>50% hepatic involvement; >25% lung involvement, or abdominal mass >/= 10 cm), central nervous system metastases, or unresolved bowel obstruction or diarrhoea (...) the costs were incurred over a short time period, due to the short survival of patients with metastatic colorectalcancer. The unit costs were generally reported separately from the quantities of resources used. The economic evaluation included drug acquisition costs, administration costs (inpatient stay and disposable equipment), and expenses associated with complications of treatment and disease. These expenses were for visits to the oncologist, radiologist, gynaecologist, surgeon, dermatologist
trial in advanced colorectalcancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A:1945-54. Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectalcancer. Annals of Oncology 1996;7:961-5. Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /economics /therapeutic use; ColorectalNeoplasms /drug therapy /economics (...) An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectalcancer An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectalcancer An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectalcancer Groener M G, van Ineveld B M, Byttebier G, van Hout B A, Rutten F F Record Status This is a critical abstract of an economic evaluation that meets the criteria
a combination of 5-fluorouracil and calcium folinate. Various dose and administration schedules were used. Chronomodulation, the administration of varying doses of oxaliplatin at differing times of the day, was used in some studies. Participants included in the review Patients who had been diagnosed as having metastatic colorectalcarcinoma and who were aged between 18 and 75 years. The patients were generally required to have biopsy-proven adenocarcinoma, measurable recurrent or metastatic disease, a WHO (...) , Adkins J C, Plosker G L, Goa K L. Oxaliplatin: a review of its use in the management of metastatic colorectalcancer. Drugs and Aging 1999; 14(6): 459-475 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Animals; Antineoplastic Agents /therapeutic use; Clinical Trials as Topic; ColorectalNeoplasms /drug therapy /pathology; Drug Interactions; Humans; In Vitro Techniques; Neoplasm Metastasis /drug therapy; Organoplatinum Compounds /adverse effects /pharmacokinetics /pharmacology
to September 1998) and a review of the references was undertaken to identify English-language articles. The search was undertaken using the MeSH terms 'colorectal, colon, and rectal neoplasm' or textword terms 'colorectal, colon, and rectal cancer' combined with the MeSH terms 'estrogen, estrogen replacement therapy' or textword terms 'hormone replacement therapy, postmenopausal hormones, noncontraceptive hormones'. Study selection Study designs of evaluations included in the review Observational studies (...) analyses were performed within categories of hormone use (ever use, current use and duration of current use) and cancer type (coloncancer, rectal cancer, colorectalcancer). Included studies used several cut off points for duration of hormone use (e.g. 4, 5, and 6 years). Participants included in the review Postmenopausal women. Pre-menopausal women were excluded from the analysis where possible. Outcomes assessed in the review Estimates of the risk of cancers of the colon or rectum in relation
being conducted by the Women's Health Initiative which will examine coloncancer as a primary outcome. Results from this study are expected in 2006. Bibliographic details Nanda K, Bastian L A, Hasselblad V, Simel D L. Hormone replacement therapy and the risk of colorectalcancer: a meta-analysis. Obstetrics and Gynecology 1999; 93(5 Part 2 Supplement S): 880-888 PubMedID Indexing Status Subject indexing assigned by NLM MeSH ColorectalNeoplasms /mortality /prevention & Female; Hormone Replacement (...) were extracted by two authors using a pretested data extraction sheet with disagreements being resolved by consensus: study design; study size; tumour site; multivariable adjusted odds ratio (OR) or relative risk (RR) with 95% confidence intervals; years of HRT use; and factors used to estimate adjusted RR. Relative risk and 95%CI were calculated by recency of HRT use, by duration of use of HRT, and by coloncancer subsite. Women who had never used HRT were used as the reference group. The OR from
in the review Prospective and retrospective studies were eligible for inclusion. Randomised trials were given more weight, but data from non-randomised trials, case series and surveys were also included. Specific interventions included in the review Studies of any monitoring strategy to detect people with asymptomatic metastatic disease following surgery for colon or rectal cancer were eligible for inclusion in the review. The interventions included in the review were colonoscopy, rigid and flexible (...) surgery for sporadic cases of colon or rectal cancer and were symptom free at study entry were eligible for inclusion. Where possible, the authors considered colon and rectal cancers separately. People with hereditary cancers were excluded. Outcomes assessed in the review Studies were eligible for inclusion if they included data on overall and disease-free survival, quality of life, toxicity, or cost-effectiveness. How were decisions on the relevance of primary studies made? An expert panel
. Authors' conclusions Positron emission tomography was more sensitive and specific than CT in the detection of recurrent colorectalcancer. Preoperative detection of a nonresectable tumour by PET may avoid unnecessary surgery, and thereby reduce the cost of patient treatment. CRD COMMENTARY - Selection of comparators The strategy of CT imaging was explicitly regarded as the comparator because it was a procedure routinely performed in the context in question. You, as a database user, should consider (...) Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectalcancer Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectalcancer Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectalcancer Valk P E, Abella-Columna E, Haseman M K, Pounds T R, Tesar R D, Myers R W, Greiss H B, Hofer G A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectalcancer: a randomised trial. European Organisation for Research and Treatment of CancerGastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv There is conflicting evidence on the efficacy of regional adjuvant chemotherapy, via portal-vein infusion (PVI), after resection of colorectalcancer. We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (...) died. 5-year survival did not differ significantly between the groups (73 vs 72%; 95% Cl for difference -6 to 4). The control and PVI groups were also similar in terms of disease-free survival at 5 years (67 vs 65%) and the number of patients with liver metastases (79 vs 77%).PVI of fluorouracil, at a dose of 500 mg/m2 for 7 days, cannot be recommended as the sole adjuvant treatment for high-risk colorectalcancer after complete surgical excision. However, these results cannot eliminate a small
1998LancetControlled trial quality: predicted high
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectalcancer. In phase II trials, irinotecan is active in patients with advanced colorectalcancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known.267 patients who had failed to respond to first-line fluorouracil, or whose disease had progressed after treatment with first-line (...) and 8.5 months (p=0.06) for irinotecan and fluorouracil, respectively. Both treatments were equally well tolerated. QoL was similar in both groups.Compared with fluorouracil by continuous infusion second-line irinotecan significantly improved survival in patients with advanced colorectalcancer.
-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group.Our study shows that despite the side-effects of treatment, patients who have metastatic colorectalcancer, and for whom fluorouracil has failed, have a longer survival, fewer tumour-related symptoms, and a better quality of life when treated with irinotecan than with supportive care alone. (...) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectalcancer. In phase II studies, irinotecan is active in metastatic colorectalcancer, but the overall benefit has not been assessed in a randomised clinical trial.Patients with proven metastatic colorectalcancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks
anti-tumour activity. These results have been confirmed in reports of randomised controlled trials which show a statistically significant improved survival for patients on irinotecan compared to either best supportive care or 5FU. Irinotecan appears to be a promising new agent in the treatment of colorectalcancer. However it is currently not possible to assess its cost effectiveness in detail. In common with other cytotoxic agents irinotecan is commonly associated with adverse reactions. Frequent (...) Irinotecan as second line chemotherapy in colorectalcancer (preliminary report) Irinotecan as second line chemotherapy in colorectalcancer (preliminary report) Irinotecan as second line chemotherapy in colorectalcancer (preliminary report) Smithies A, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smithies A, Stein K
Authors' objectives To summarise the research evidence which informed the Department of Health's Clinical Outcomes Group's guidance on commissioning cancer services, based on a series of systematic reviews. Authors' conclusions Colorectal (bowel) cancer is the second most common cause of cancer death in the UK. The disease is curable when not too far advanced and UK survival rates could be substantially improved with better management. Project page URL Indexing Status Subject indexing assigned by CRD (...) The management of colorectalcancer The management of colorectalcancer The management of colorectalcancer NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. The management of colorectalcancer. York: University of York. Effective Health Care 3(6). 1998
development and implementation. J Clin Oncol 1995;13:502-12. 2. Germond C, Maroun, J, Zwaal C, Wong S, Gastro-intestinalCancerDisease Site Group. Use of raltitrexed in the management of metastatic colorectalcancer. Curr Oncol 1999;6:217-23. Indexing Status Subject indexing assigned by CRD MeSH Antimetabolites, Antineoplastic /administration & ColorectalNeoplasms /drug therapy; Quinazolines /administration & Thiophenes /administration & dosage; dosage; dosage AccessionNumber 12003008191 Date (...) Use of raltitrexed (Tomudex) in the management of metastatic colorectalcancer Use of raltitrexed (Tomudex) in the management of metastatic colorectalcancer Use of raltitrexed (Tomudex) in the management of metastatic colorectalcancerGastrointestinalCancerDisease Site Group CRD summary This review assessing the role of raltitrexed in the management of metastatic colorectalcancer found that raltitrexed appears to have equivalent survival benefits to 5-fluorouracil plus leucovorin in people
resection may, therefore, have been overstated in the review's conclusion. Implications of the review for practice and research The authors did not state any implications for practice or further research. Bibliographic details Rosen M, Chan L, Beart R W, Vukasin P, Anthone G. Follow-up of colorectalcancer: a meta-analysis. Diseases of the Colon and Rectum 1998; 41(9): 1116-1126 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; ColorectalNeoplasms /diagnosis (...) to changes in symptoms only. Participants included in the review Patients who had undergone resection for colorectalcancer were included. Outcomes assessed in the review The outcome measures were the curative resection rates after recurrent cancer, the survival rates of curative re-resections, the length of survival after recurrence, and the cumulative 5-year survival. Curative resection for recurrent cancer was defined as no tumour left behind and no evidence of disease for at least 30 days post
A meta-analysis of hormone replacement therapy and coloncancer in women A meta-analysis of hormone replacement therapy and coloncancer in women A meta-analysis of hormone replacement therapy and coloncancer in women Hebert-Croteau N Authors' objectives To investigate the association between hormone replacement therapy (HRT) and coloncancer. Searching MEDLINE and Cancerlit were searched (dates not stated). Keywords included: colorectalneoplasm or colonicneoplasm or gastrointestinal (...) of hormone replacement therapy and coloncancer in women. Cancer Epidemiology, Biomarkers and Prevention 1998; 7(8): 653-659 Other publications of related interest 1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. 2. MacLennan SC, MacLennan AH, Ryan P. Colorectalcancer and oestrogen replacement therapy. A meta-analysis of epidemiologic studies. Medical Journal of Australia 1995;162:491-3. Indexing Status Subject indexing assigned by NLM MeSH Adult; Age
in the review Patients diagnosed with colon or rectal cancer. The mean age of participants was 63 years and 61% were male. Outcomes assessed in the review Outcomes assessed were: tumour response and survival rates. Complete response (CR) and partial response (PR) criteria adopted in individual trials followed the World Health Organization (WHO) recommendations and were identical in all trials. Patients with minimal response, stable disease, or tumour progression were considered to have had no response (...) to study this approach in the surgical adjuvant setting. Bibliographic details Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectalcancer. Journal of Clinical Oncology 1998; 16(1): 301-308 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Antimetabolites, Antineoplastic /administration & ColorectalNeoplasms /drug therapy /mortality; Fluorouracil /administration & Humans; Infusions, Intravenous